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Background: Systemic sclerosis (SSc) is an autoimmune chronic disease characterized by diffuse fibrosis involving
several organs, including heart. Aim of our study was to analyze left ventricular (LV) myocardial deformation, by use
of 2D strain, in asymptomatic SSc patients with normal LV ejection fraction.
Methods: We enrolled 29 SSc patients (28 female, 65±4 years) and 30 controls (23 female, 64±2 years).
Echocardiographic study with tissue Doppler imaging (TDI) and 2D strain analysis was performed; moreover,
patients were submitted to a two-year follow-up for the occurrence of cardiovascular events.
Results: Standard echocardiographic parameters and TDI velocities were comparable between groups. LV
longitudinal (LS) and circumferential (CS) strains were lower in patients than in controls (−13.1±4.8 vs −22.6±4.1,
p < 0.001; -15.3±6.2 vs −20.4±5.6, p = 0.001), whereas radial strain (RS) was comparable between groups; moreover,
a significant correlation of LS and CS with serum levels of Scl-70 antibodies was found (r = 0.74, p = 0.001; r = 0.53,
p = 0.025). In addition, patients with cardiovascular events during follow-up showed a greater impairment of LS
and CS (−10.3±2.5 vs −14.4±4.1, p = 0.015; -14.2±3.1 vs −20.1±1.6, p = 0.048) and higher values of Scl-70 antibodies
serum levels (p = 0.047).
Conclusion: The impairment of LV function, often subclinical, worsens prognosis of SSc patients, leading to
increased risk of cardiovascular complications. 2D strain, allowing the early detection of LV abnormalities and the
identification of patients at greater cardiovascular risk, may be a useful tool in order to provide a more accurate
management of SSc patients.
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Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by inflammation, widespread vascular lesions and
fibrosis involving various tissues and organs such as skin,
lungs, gastrointestinal tract, kidneys, heart and blood ves-
sels [1-3]. Multiple cardiac abnormalities, including ven-
tricular arrhythmias, conduction disturbances, pericardial
effusion, myocardial fibrosis and ischaemia, have been, fre-
quently, reported in SSc and associated to a worse clinical* Correspondence: maurizio.cusma@tiscali.it
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distribution, and reproduction in any mediumcourse of the disease [4]. In particular, right ventricular
(RV) dysfunction, commonly associated with pulmonary
hypertension, has been, traditionally, considered as the
hallmark of cardiac involvement in SSc, whereas left ven-
tricular (LV) involvement, confirmed at post-mortem
examinations, has been less extensively evaluated [5,6].
Since LV abnormalities are often subclinical and detectable
by standard echocardiography only in the advanced stage
of the disease, the assessment of myocardial deformation,
by use of two-dimensional (2D) strain, may be particularly
valuable in the identification of early LV changes in SSc,
allowing a more adequate management of these patients
with particular regards to the prevention of overt cardio-
vascular complications.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Cusmà Piccione et al. Cardiovascular Ultrasound 2013, 11:6 Page 2 of 8
http://www.cardiovascularultrasound.com/content/11/1/6Aim of the present study was to evaluate LV myocardial
deformation, by use of 2D strain, with particular regards
to its impact on clinical outcome, in asymptomatic SSc
patients with preserved LV ejection fraction (EF).
Methods
Study population
We enrolled 29 consecutive asymptomatic patients (28
female, mean age 65±4 years) affected by SSc and 30
healthy subjects (23 female, 64±2 years). All patients
fulfilled the criteria for SSc proposed by the American
College of Rheumatology [7] and were affected by dif-
fuse form of the disease with a time of 15±8 years from
diagnosis. The therapeutic regimen employed from the
onset of disease’s symptoms/signs, was, in all patients,
the association of prednisolon and prostaglandin E1
(alprostadil). Pulmonary involvement was investigated
in each patient by means of chest radiograph and com-
puted tomography scan in order to detect interstitial
fibrosis. Clinical examination, serological tests and
echocardiographic study were performed in each sub-
ject. Furthermore, follow-up information was obtained
from telephonic interviews with patients and controls,
their relatives or their physicians every six months up
to two years. Predefined end-points for cardiovascular
events were the new onset of symptoms and/or signs of
heart failure and coronary artery disease, atrial fibrilla-
tion or cardiovascular death during follow-up. Patients
with arterial hypertension (SBP/DBP > 140/90 mmHg),
documented coronary artery disease, moderate to se-
vere valvular heart disease, regional myocardial asyner-
gies, impaired LV EF (< 55%), atrial fibrillation, renal
insufficiency (defined in case of creatinine clearance
less than 90 ml/min/1.73 m2) and significant pulmonary
interstitial fibrosis were excluded. Subjects with inad-
equate acoustic window were also ruled out (4 patients
were excluded). All patients gave written informed
consent to our study protocol that was supported by
our hospital’s Ethical Committee. The authors of this
manuscript have certified that they comply with the
Principles of Ethical Publishing in the International Journal
of Cardiology [8].
Echocardiographic study
All echocardiographic examinations were performed with
a My-Lab 50 echocardiographic machine (Esaote, Florence,
Italy), equipped with a 2.5-MHz phased array transducer.
Two-dimensional images were obtained from standard
views (parasternal long-axis and short axis views, apical
4-chamber, 2-chamber and long-axis views). In each sub-
ject LV end-diastolic (EDV), end-systolic (ESV) volumes
and biplane Simpson’s EF were measured. LV mass was
calculated, according to Devereux’s formula, by M-mode
technique, from mid-ventricular short axis view andcorrected for body surface area [9]. Qualitative assessment
of regional wall motion was performed according to
the 16-segments model of the American Society of
Echocardiography [10]. Mitral inflow measurements were
obtained from apical 4-chamber view by placing the sample
volume at mitral leaflet tips, and peak velocities of E and A
waves, E/A ratio and E-wave deceleration time were mea-
sured. RV end-diastolic diameters were measured, as re-
commended by the American Society of Echocardiography,
in parasternal short axis (RVOT Prox) and apical
4-chamber views at basal level (RVD1) [11]. Tricuspid an-
nular plane systolic excursion (TAPSE) was measured with
M-mode cursor positioned at the free wall angle of the tri-
cuspid valve annulus; furthermore, RV fractional area
change (FAC), defined as (end-diastolic area – end-systolic
area)/end-diastolic area × 100, was calculated from apical
4-chamber view. Tricuspid valve regurgitation peak vel-
ocity, measured by use of continuous-wave Doppler tech-
nique, was employed to estimate systolic pulmonary arterial
pressure (sPAP).
Tissue Doppler imaging (TDI) myocardial velocities
were measured in the apical 4-chamber view, placing the
sample volume at the junction of LV interventricular
septum with mitral annulus. Peak systolic (s’), early (e’)
and late diastolic (a’) myocardial velocities were recorded
and E/e’ ratio was calculated.
In each subject, strain analysis was performed offline by
use of a dedicated software package (XStrain TM, Esaote,
Florence, Italy). With this software, already validated in
previous studies [12,13], segmental evaluation of strain
was performed from digitalized 2D videoclips of basal,
mid-ventricular, apical parasternal short axis and of 4- and
2-chamber apical views. Endocardial border was manually
traced as a sequence of 13 equidistant points and frame-
by-frame displacement of these points was automatically
evaluated. Global and segmental values of radial, circum-
ferential (subendocardial layer) and longitudinal strains
(RS, CS and LS respectively) were obtained. Tracking qual-
ity was verified for each segment and low quality images
were excluded from strain analysis.Statistical analysis
Data were expressed as mean ± SD. Statistical analysis was
performed using the SPSS statistical software (SPSS v.17
for Windows, SPSS. Inc., Chicago, IL, USA). Independent
T and Chi-square tests were used for comparison between
groups of continuous and categorical variables, respect-
ively. Pearson’ and Spearman’s coefficients were used for
correlations between variables. To assess the reproducibil-
ity of measurements of myocardial strains, Bland-Altman
analysis was performed for intra-observer and inter-
observer variability. P-values of 0.05 or less were consid-
ered significant.







LV EDV, ml 79±11 83±15 ns
LV ESV, ml 27±7 33±14 ns
LV EF, % 65±1 64±6 ns
LV Mass, g/m2 68.9±5.9 69.6±4.6 ns
Mitral E peak velocity, cm/s 64±9.5 58.5±12.4 ns
Mitral A peak velocity, cm/s 70±9.2 66.3±14.2 ns
Mitral E/A ratio 0.8±0.3 0.8±0.1 ns
Mitral E deceleration time,
ms
188.1±43 180.7±28 ns
RVOT Prox, mm 29.9±5.6 30.2±3.7 ns
RVD1, mm 33.1±2.9 33.1±2.9 ns
TAPSE, mm 22.5±3.1 21.6±2.9 ns
RV FAC, % 48.5±6.9 46.9±6.3 ns
sPAP, mmHg 21.8±6 37.4±9 < 0.001
LV: left ventricular; EDV and ESV: end-diastolic and end-systolic volumes,
respectively; EF: ejection fraction; RVOT prox: right ventricular outflow tract
proximal diameter; RVD1: right ventricular inflow diameter at basal level;
TAPSE: tricuspid annular plane systolic excursion; FAC: fractional area change;
sPAP: systolic pulmonary arterial pressure.
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General characteristics and prevalence of cardiovascular
risk factors of SSc patients and healthy controls are
shown in Table 1. There were no significant differences
between patients and controls regarding age, systolic/
diastolic blood pressure and prevalence of main cardio-
vascular risk factors with the only exception of sex be-
cause of a greater prevalence of female gender in SSc
group (p = 0.03). As shown in Table 2, the two groups
did not differ from each other with respects to LV mass,
EDV, ESV, EF, Doppler mitral diastolic velocities and
E-wave deceleration time as well as to RV diameters,
TAPSE and FAC; differently, sPAP was mildly increased
in patients with respects to controls (p < 0.001).
Results of parameters obtained from TDI and 2D
strain analysis are listed in Table 3. TDI systolic and dia-
stolic velocities as well as E/e’ ratio were comparable be-
tween patients and controls; on the other hand, CS and
LS were significantly lower in patients than in healthy
subjects (p = 0.001 and p < 0.001 respectively) [Figure 1;
Figure 2, upper panels], whereas no significant differ-
ences were observed with respects to RS.
In addition, in the subgroup of patients resulted positive
to Scl-70 antibodies (58% of overall group of patients), a
significant linear correlation between serum levels of Scl-70
antibodies and both LS and CS was found (r = 0.74
p = 0.001 and r = 0.53 p = 0.025, respectively) [Figure 3].
Follow-up information was available for 26 (89%) of 29
patients and 22 (73%) of 30 healthy subjects. Mean follow-
up time was 20±4 months. During follow-up, the prede-
fined cardiovascular events were reached in 12 patients
with the occurrence of atrial fibrillation in 6 patients (50%)
and symptoms/signs of heart failure (fatigue, dyspnoea, per-
ipheral oedema) in the remaining 6 patients (50%); no car-
diovascular events were observed in healthy subjects. As
shown in Table 4, no significant differences, with respects






Age, yrs 64±2 65±4 ns
Female sex, n (%) 23 (76) 28 (96) 0.03
SBP, (mmHg) 120±11 125±15 ns
DBP, (mmHg) 79±8 74±9 ns
Diabetes, n (%) 3 (10) 3 (10) ns
Dyslipidemia, n (%) 10 (33) 10 (34) ns
Smoking, n (%) 3 (10) 2 (6) ns
Disease’s duration, yrs - 15±8 -
Scl-70 antibodies, n (%) - 17 (58) -
Serum levels of Scl-70 antibodies, U/ml - 46.9±41.2 -
SBP and DBP: systolic and diastolic blood pressure, respectively.prevalence of main cardiovascular risk factors and standard
echocardiographic parameters. On the other hand, as sum-
marized in Table 5, despite a not significant trend for lower
TDI velocities and higher E/e’ ratio in patients showing
events during follow-up, only LS and CS were significantly
reduced in patients with events when compared to the
others [Figure 2, lower panels]. Furthermore, in patients
with cardiovascular events, a greater prevalence of positivity
to Scl-70 antibodies (83%) with, in addition, markedly
increased values of serum levels of Scl-70 antibodies were
found (p = 0.03 and p = 0.047, respectively).Reproducibility
We obtained good intra-observer and inter-observer
reproducibility in the measurement of LS (−1.3±6.2%Table 3 Left ventricular tissue Doppler imaging velocities
and global strains in controls and patients
CONTROLS (N=30) SSC (N=29) p
Septal s’, cm/s 8.4±0.3 8.0±0.3 ns
Septal e’, cm/s 9.5±1.5 8.9±1.7 ns
Septal a’, cm/s 9.7±1.2 9.6±1.5 ns
E/e’ ratio 6.8±1.3 6.9±1.4 ns
RS, % 38.5±9.3 35.5±8.1 ns
CS, % −20.4±5.6 −15.3±6.2 0.001
LS, % −22.6±4.1 −13.1±4.8 < 0.001
RS, CS and LS: radial, circumferential and longitudinal strain, respectively.
Figure 1 Examples of left ventricular circumferential strain, from mid-ventricular parasternal short axis view [upper panels], and of
longitudinal strain, from 4-chamber apical view [lower panels], in a SSc patient [left] and in an healthy subject [right].
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respectively) and RS (4.7±12% and 5.1±17%, respectively).
Discussion
LV myocardial involvement, even though subclinical
and, thus, frequently underestimated, is associated to a
worse prognosis of the disease, leading to increased risk
of cardiovascular complications in SSc patients [14,15].
Since standard echocardiography, with the assessment of
LVEF and PW Doppler mitral inflow parameters, proved
to be, in various diseases and SSc as well, often inad-
equate to identify early myocardial abnormalities, other
diagnostic tools are needed in order to detect the onset
of cardiac involvement [16-18]. In this respect, TDI and,
more recently, 2D strain, have been shown to provide a
more accurate evaluation of myocardial function.
The main findings of the present study are: 1) the im-
pairment of both LS and CS, detectable only by means
of 2D strain, in asymptomatic SSc patients in the ab-
sence of significant differences regarding other echocar-
diographic parameters, including TDI, in comparison
with healthy subjects; 2) a significant correlation of both
LS and CS with serum levels of Scl-70 antibodies; 3) a
greater impairment of LS and CS in patients showing
cardiovascular events during follow-up; 4) higher valuesof serum levels of Scl-70 antibodies in patients with car-
diovascular events.
Along with multiple reports of RV abnormalities in
SSc, usually secondary to vascular and interstitial lung
disease resulting into pulmonary hypertension [19,20], a
primary LV involvement related to organic and func-
tional alterations of microvasculature, including reduced
coronary flow reserve, has been observed [21-24]; in
support of these data, studies performed using single
photon emission computerized tomography (SPECT)
have shown multiple ventricular perfusion defects in the
absence of coronary artery disease documented by angi-
ography, particularly in patients with pulmonary hyper-
tension [25,26]. Owing to this vasculopathy, a “patchy”
myocardial fibrosis develops, with a distribution unre-
lated to coronary vessels territories [27-30], leading, as
consequences, to multiple LV diastolic and systolic ab-
normalities including lower TDI velocities and impaired
myocardial deformation [31,32]. In this respect, a direct
relation between myocardial reflectivity, evaluated by
integrated cardiac ultrasound backscatter, and LV de-
formation parameters was found by Mele et al. [33],
with a more pronounced impairment of myocardial
function in patients with diffuse SSc with respects to
the limited form of disease, thus, confirming the pivotal
Figure 2 Histograms, with standard deviation bars, of left ventricular longitudinal (LS) and circumferential (CS) strains between
patients and controls [upper panels, A and B] and between patients with and without cardiovascular events [lower panels, C and D].
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SSc. Similarly, previous studies have shown, particularly
in diffuse SSc, various myocardial function abnormal-
ities including lower TDI velocities and impaired strain
despite normal standard echocardiographic parameters
[34,35]. In this respect, TDI, although characterized by ex-
cellent temporal resolution, presents some limitations in-
cluding angle dependency, the impossibility to distinguish
passive from active motion and arbitrary choice of regions
of interest [36]; on the other hand, 2D strain, even though
currently limited by a still lacking standardization of refer-
ence values particularly due to inter-vendor variability,
proved to be more sensitive and accurate, than TDI, in the
assessment of myocardial deformation and, therefore, in
the detection of early myocardial abnormalities in various
diseases [37,38]. Our findings support these data, as we
observed impaired LS and CS in spite of preserved other
echocardiographic parameters including TDI velocities.
Similarly, Spethmann et al. [39] reported, in SSc patients
with normal LVEF, an impairment of LV global longitu-
dinal strain and strain rate, assessed by use of speckle-
tracking echocardiography, with, especially, a reduceddeformation of basal myocardial segments. Furthermore,
an association of impaired LS and CS with lower values of
peak VO2 and abnormal Holter electrocardiographic find-
ings has been, previously, observed in SSc patients [40]. In
this respect, the impairment of LV longitudinal deform-
ation may reflect, despite preserved LVEF, the early onset
of cardiac involvement, since longitudinal subendocardial
fibers are known to be, particularly, vulnerable to myocar-
dial damage and ischemia. Furthermore, in patients with
more advanced LV myocardial involvement, an impair-
ment of CS, in addition to abnormal longitudinal deform-
ation, may occur, as found in our study.
We observed, moreover, particularly impaired LS and
CS in patients with cardiovascular events during follow-
up, whereas, interestingly, no significant differences,
with respects to the occurrence of cardiovascular events,
were found regarding other echocardiographic para-
meters, such as LVEF, diastolic mitral inflow parameters,
RV measurements and TDI velocities. In this respect, so
far, to the best of our knowledge, only in our study, car-
diovascular events have been found to be associated with
impaired LV longitudinal and circumferential myocardial
Table 4 General characteristics and standard echocardiographic parameters in patients with and without
cardiovascular events during follow-up
EVENTS (N=12) NO EVENTS (N=14) p
Age, yrs 60±2 63±4 ns
SBP, (mmHg) 128±9 124±12 ns
DBP, (mmHg) 76±10 73±8 ns
Diabetes, n (%) 2 (16) 1 (7) ns
Dyslipidemia, n (%) 4 (33) 6 (50) ns
Smoking, n (%) 1 (8) 1 (7) ns
Scl-70 antibodies, n (%) 10 (83) 4 (28) 0.03
Serum levels of Scl-70 antibodies, U/ml 83.9±57.6 17.1±41.7 0.047
LV EDV, ml 85±7 82±6 ns
LV ESV, ml 34±3 30±4 ns
LV EF, % 62±3 65±2 ns
LV Mass, (g/m2) 72.6±4.3 68.4±3.9 ns
Mitral E peak velocity, (cm/s) 63.2±8.5 59.5±9.4 ns
Mitral A peak velocity, (cm/s) 62.1±6.7 67.9±9.2 ns
Mitral E/A ratio 1.0±0.1 0.8±0.2 ns
Mitral E deceleration time, (ms) 176.4±12 182.7±18 ns
RVOT Prox, mm 30.9±2.9 30.1±2.8 ns
RVD1, mm 33.7±2.6 32.9±2.4 ns
TAPSE, mm 20.9±3.1 21.8±2.8 ns
RV FAC, % 46.3±5.8 47.1±5.4 ns
sPAP, (mmHg) 38.5±3 36.4±7 ns
SBP and DBP: systolic and diastolic blood pressure, respectively. LV: left ventricular; EDV and ESV: end-diastolic and end-systolic volumes, respectively; EF: ejection
fraction; RVOT prox: right ventricular outflow tract proximal diameter; RVD1: right ventricular inflow diameter at basal level; TAPSE: tricuspid annular plane systolic
excursion; FAC: fractional area change; sPAP: systolic pulmonary arterial pressure.
Figure 3 Linear regression lines between longitudinal strain (LS) and Scl-70 antibodies serum levels [left panel] and between
circumferential strain (CS) and Scl-70 antibodies serum levels [right panel].
Cusmà Piccione et al. Cardiovascular Ultrasound 2013, 11:6 Page 6 of 8
http://www.cardiovascularultrasound.com/content/11/1/6
Table 5 Left ventricular tissue Doppler imaging velocities
and global strains in patients with and without
cardiovascular events during follow-up
EVENTS (N=12) NO EVENTS (N=14) p
Septal S’, cm/s 7.8±0.2 8.1±0.1 ns
Septal E’, cm/s 8.6±0.9 9.0±0.6 ns
Septal A’, cm/s 9.3±1.0 9.8±1.1 ns
E/e’ ratio 7.3±1.2 6.7±1.4 ns
RS, % 30.1±5.8 33.2±3.3 ns
CS, % −14.2±3.1 −20.1±1.6 0.048
LS, % −10.3±2.5 −14.4±4.1 0.015
RS, CS and LS: radial, circumferential and longitudinal strain, respectively.
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obtained by Hinchcliff et al. [41], concerning the associ-
ation between LV TDI velocities and increased risk of
death in SSc, suggest that new echocardiographic techni-
ques, such as 2D strain, may be useful not only in the
detection of early LV myocardial involvement in SSc but
also in the identification of patients at greater risk of
cardiovascular events. In this regard, the early diagnosis
of cardiovascular involvement in these patients may be
particularly valuable in order to provide a more ad-
equate therapeutic management, such as the beginning
of cardioprotective drugs including inhibitors of renin-
angiotensin-aldosterone system and beta-blockers, even
though this therapeutic approach has not been widely
investigated, so far, in such a clinical setting.
In addition, we found a significant relation between the
impairment of LS and CS and higher serum concentra-
tions of Scl-70 antibodies, with particularly lower values of
myocardial deformation at very high serum levels of anti-
bodies. Moreover, very high values of Scl-70 antibodies
serum levels were observed in patients showing cardiovas-
cular events. These findings support the prognostic rele-
vance of the abnormalities of LV myocardial deformation
in these patients, since Scl-70 antibodies, found in about
15–20% of patients, portend a poorer clinical outcome of
the disease, as widely reported [42]. Although reports have
been, so far, pointed out on the association of these anti-
bodies with restrictive lung disease, pulmonary hyperten-
sion and RV functional abnormalities [43], to date a
relation between Scl-70 antibodies and LV involvement in
SSc, to the best of our knowledge, has not been, previ-
ously, described.
Limitations
As a limitation of our study, we enrolled a relatively
small number of patients. This depends on the low
prevalence of SSc (estimated between 3 and 24/100.000)
[44]; the size of our population, however, doesn’t differ
from that reported in previous studies on this topic. In
addition, we could not directly evaluate myocardialfibrosis, by use of cardiac MRI, ultrasound calibrated
integrated backscatter or myocardial biopsies, and, thus,
we can only hypothesize a relation between fibrosis and
the cardiac abnormalities observed in our study. More-
over, as a further limitation of our study, we obtained
follow-up information of subjects from telephonic inter-
views and, thus, we could not perform clinical and echo-
cardiographic examination at the time of the occurrence
of cardiovascular events.
Conclusions
Early impairment of LV function, even though associated
to a worse clinical course of SSc, is, frequently, subclinical
and hardly detectable by means of standard echocardiog-
raphy. New echocardiographic techniques, such as, par-
ticularly, 2D strain, facilitate the detection of early LV
function abnormalities occurring in SSc and, moreover,
can be helpful in the identification of patients at increased
risk of cardiovascular events. Thus, 2D strain may be a
useful diagnostic tool, in addition to standard echocardi-
ography, in the routine evaluation of SSc patients in order
to provide a more adequate management of these patients
with particular regards to the prevention of the occurrence
of cardiovascular complications.
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